CM24

News alerts, weekly reports and conference planners

Company:

Merck (MSD), Purple Biotech

Drug class:

CEACAM1 inhibitor

‹

›

1year

FW-2020-1: A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=79, Completed, Famewave Ltd. | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Sep 2024

1 year ago

Trial completion • Trial completion date

Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • Onivyde (nanoliposomal irinotecan) • CM24

almost2years

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=79, Active, not recruiting, Famewave Ltd. | Trial completion date: Mar 2024 --> Jan 2025 | Trial primary completion date: Feb 2024 --> Dec 2024

almost 2 years ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • Onivyde (nanoliposomal irinotecan) • CM24

2years

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=79, Active, not recruiting, Famewave Ltd. | Recruiting --> Active, not recruiting

2 years ago

Enrollment closed

Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • Onivyde (nanoliposomal irinotecan) • CM24

2years

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=79, Recruiting, Famewave Ltd.

2 years ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • Onivyde (nanoliposomal irinotecan) • CM24